¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lupus Vasculitis, Central Nervous System"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
¿µ¹® digestive system ÇÑ±Û ¼ÒÈ­±â°èÅë
¼³¸í   
  ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ­, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼­ ºÎ¸£´Â ¸».
¿µ¹® cardiovascular system ÇÑ±Û ½ÉÀåÇ÷°ü°è
¼³¸í   
  ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇϴ ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼­ À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® TNM staging system ÇÑ±Û Á¾¾çº´±âºÐ·ù°èÅë
¼³¸í   
  Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤Çϴ ÇÑ ¹æ¹ý.
  
  T´Â Tumor(Á¾¾ç)¸¦ ¶æÇϸ砿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀǠħÀ±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î Ä§À±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù.
  
  NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç Ä§¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù.
  
  MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇϸ砿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù.
  
  ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀΠº´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • central chemoreceptor
    ÁßÃßÈ­Çмö¿ëü
  • central cord syndrome
    Áß½Éô¼öÁõÈıº
  • central core disease
    Áß½ÉÇÙº´, Áß½ÉÄھ
  • central cyanosis
    Áß½Éû»öÁõ
  • central deafness
    ÁßÃß³­Ã»
  • central disciform retinopathy
    Á߽ɿø¹ÝÇü¸Á¸·º´(Áõ)
  • central excitatory state
    ÁßÃßÈïºÐ»óÅÂ
  • central fiber
    Á߽ɼ¶À¯
  • central fixation
    Áß½ÉÁÖ½Ã
  • central fovea
    Ȳ¹ÝÁ߽ɿÀ¸ñ, ¸Á¸·Á߽ɿÍ
  • central gray
    Áß½Éȸ»öÁú
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • central hemorrhagic necrosis
    Áß½ÉÃâÇ÷±«»ç
  • central incisor
    Á߽ɾմÏ, ÁßÀýÄ¡
  • central insertion
    Á߽ɺÎÂø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • central cataract
    Á߽ɹ鳻Àå
  • central chemoreceptor
    ÁßÃßÈ­Çмö¿ëü
  • central cyanosis
    Áß½Éû»öÁõ
  • central deafness
    ÁßÃß³­Ã»
  • central fiber
    Á߽ɼ¶À¯
  • central fixation
    Áß½ÉÁÖ½Ã
  • central fovea
    Ȳ¹ÝÁ߽ɿÀ¸ñ
  • central gray
    Áß½Éȸ»öÁú
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • central insertion
    Á߽ɺÎÂø
  • central karyosome
    Áß½ÉÇÙ¼Òü
  • central nucleus
    Áß½ÉÇÙ
  • central pain
    ÁßÃß¼ºÅëÁõ
  • central pulse
    Á߽ɸƹÚ
  • central resection
    Áß¾ÓÀýÁ¦(¼ú)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Haversian system
    ÇϹö½º°è
  • Hypothalamic-hypophysial portal system
    ½Ã»óÇϺÎ-Çϼöü ¹®¸Æ°è(ãÊßÉù»Ý» ù»á÷ô÷ Ú¦ØæÍ§)
  • Immune system
    ¸é¿ªÃ¼°è(Øóæ¹ô÷ͧ)
  • International System of Unit
    ±¹Á¦´ÜÀ§°è
  • Jackson-Rees anesthetic circuit system
    Àè½¼-¸® ¸¶ÃëÀåÄ¡
  • Kell blood group system
    ÄÌÇ÷¾×Çü±º
  • Kell system
    ÄÌÇ÷¾×Çü.
  • Kidd blood group system
    ۵åÇ÷¾×Çü±º
  • Lewis blood group system
    ·çÀ̽º Ç÷¾×Çü±º
  • Lutheran blood group system
    ·çÅͶõ Ç÷¾×Çü±º
  • Lymphatic system
    ¸²ÇÁ°è(¡­Í£)
  • Magills anesthetic circuit system
    ¸¶Áú¸¶ÃëÀåÄ¡
  • Mapleson anesthetic circuit system
    ¸ÅÇý¼¸¶Ãëȸ·Î
  • NADPH-dependent oxidase system
    NADPH-ÀÇÁ¸¼º »êÈ­È¿¼Ò°è
  • OS (operating system)
    ¿î¿µÃ¼Á¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nodular vasculitis
    °áÀý¼º ¸Æ°ü¿°(~ØæÎ·æú).
  • nodular vasculitis
    °áÀý¼º ¸Æ°ü¿°(¡­ØæÎ·æú)
  • retinal vasculitis
    ¸Á¸·Ç÷°ü¿°
  • rheumatoid arthritis,vasculitis
    Ç÷°ü¿°(úìηæú)
  • rheumatoid vasculitis
    ·ù¸¶Æ¼½º¾çÇ÷°ü¿°(¡­úìηæú).
  • rheumatoid vasculitis
    ·ù¸¶Æ¼½º¾çÇ÷°ü¿°(¡­åÆúìηæú)
  • segmented hyalinizing vasculitis
    ºÐÀýÀ¯¸®ÁúÇ÷°ü¿°
  • septic vasculitis
    ÆÐÇ÷¼º Ç÷°ü¿°
  • urticarial vasculitis
    µÎµå·¯±â Ç÷°ü¿°
  • vasculitis
    ¸Æ°ü¿°(ØæÎ·æú), Ç÷°ü¿°(úìηæú)
  • transverse tubular system =T system
    ÀÌ ·Î¼Ò°ü°èÅë, T°è(¡­Í§), ȾÇà¼Ò°ü°è(üôú¼á³Î·Í§) ±Ù(ÐÉ)ÀÇ .
  • breakdown nervous
    ½Å°æ¼è¾à
  • intrinsic nervous plexus
    º®¼Ó½Å°æ¾ó±â
  • myenteric nervous plexus
    ±ÙÀ°Ãþ½Å°æ¾ó±â
  • nervous asthenopia
    ½Å°æ(¼º)´«ÇÇ·Î
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Ala of central lobule
    Á߽ɼҿ±³¯°³
    [¿¾ ¿ë¾î] Á߽ɼҿ±ÀÍ
  • Central thalamic radiations
    Á߽ɽûóºÎê»ì
    [¿¾ ¿ë¾î] ±Ã½É½Ã»ó¹æ»ç
  • Central thalamic radiations
    Á߽ɽûóºÎê»ì
    [¿¾ ¿ë¾î] Áß½É½Ã»ó¹æ»ç
  • Central gelatinous substance
    Á߽ɾƱ³Áú
    [¿¾ ¿ë¾î] Á߽ɱ³¾çÁú
  • Central fovea
    Á߽ɿÀ¸ñ
    [¿¾ ¿ë¾î] Á߽ɿÍ
  • Central vein
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central veins
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central intermediate substance
    Áß½ÉÁß°£È¸»öÁú
    [¿¾ ¿ë¾î] Áß°£ÁúÁ߽ɺÎ
  • Central nucleus
    Áß½ÉÇÙ
    [¿¾ ¿ë¾î] Áß½ÉÇÙ
  • Central gray (substance)
    Áß½Éȸ»öÁú
    [¿¾ ¿ë¾î] Áß½Éȸ¹éÁú
  • Central glial cell
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] Á߽ɽŰ汳¼¼Æ÷
  • Short central artery
    ªÀºÁ߽ɵ¿¸Æ
    [¿¾ ¿ë¾î] ´ÜÁ߽ɵ¿¸Æ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • protein-synthesizing system
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷) ½Ã½ºÅÛ
  • repressible system
    ¾ïÁ¦¼º ½Ã½ºÅÛ
  • restriction-modification system
    Á¦ÇÑ ¼ö½Ä(áóãÞ) ½Ã½ºÅÛ
  • reticuloendothelial system
    ¸Á»ó³»ÇÇ(ØÑßÒÒ®ù«) ½Ã½ºÅÛ
  • Rh blood group system
    Rh Ç÷¾×Çü(úìäûúþ) ½Ã½ºÅÛ
  • RS system
    RS ½Ã½ºÅÛ
  • schlieren optical system
    ½¯¸®·» ±¤ÇÐ(ÎÃùÊ)½Ã½ºÅÛ
  • selective system
    ¼±ÅÃ(àÔ÷É) ½Ã½ºÅÛ
  • state of a system
    ½Ã½ºÅÛ »óÅÂ(ßÒ÷¾)
  • system
    ½Ã½ºÅÛ
  • transport system
    ¼ö¼Û(âÃáê)½Ã½ºÅÛ
  • T system
    T ½Ã½ºÅÛ
  • V system
    V ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CNV choroidal neovascularization; contingent negative variation; cutaneous necrotizing vasculitis
HVUS hypocomplementemic vasculitis urticaria syndrome
LCV lecithovitellin; leukocytoclastic vasculitis
RV random variable; rat virus; Rauscher virus; rectovaginal; reinforcement value; renal vein; residual ...
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
T system tubular system
HPNS High Pressure Nervous Syndrome
SNA Sympathetic nervous activity
nr nervous
BILAG British Isles Lupus Assessment Group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central amaurosis
    ÁßÃß¼º Èæ¾Ï½Ã
  • central anesthesia
    Á߽ɼº ¹«°¨°¢Áõ
    ½Å°æ ÀÓÆÞ½ºÀÇ ÁßÃß¼º Â÷´Ü°ú ÁßÃ߽ŰæÀÇ ÁúȯÀ¸·Î ÀÎÇÑ ¹«°¨°¢Áõ.
  • central aphasia
    ÁßÃß¼º ½Ç¾îÁõ
  • central areolar choroidal dystrophy
    Á߽ɼº ¿øÇü ¸Æ¶ô¸· ÀÌ¿µ¾ç
  • central artery cerebri mediae
    ÁߺΠ³úµ¿¸Æ Áß½ÉÁö
  • central artery of retina
    ¸Á¸· Á᫐ µ¿¸Æ
  • central attachment
    Á᫐ ºÎÂø
  • central bearing
    Á᫐ ÁöÁö
  • central bearing point
    Á᫐ ÁöÁöÁ¡
    Áß¾Ó ÁöÁö ÀåÄ¡ÀÇ Á¢ÃËÁ¡.
  • central biasing mechanism
    ÁßÃß ±³Â÷ ±âÀü
  • central blister
    Á߽ɼº ¼öÆ÷
  • central body
    Á᫐ ¼Òü
    À¯»çºÐ¿­ Áß¿¡ ¼º»óüÀÇ Á߽ɿ¡ ÀÖ´Â ±¸Á¶¹°.
  • central canal
    Á᫐ °ü
  • central cavernous hemangioma
    Á߽ɼº ÇØ¸é»ó Ç÷°üÁ¾
  • central chemosensitive area
    ÁßÃß È­ÇÐ °¨¼ö ¿µ¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
discoid lupus erythematosus A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop.
Synonym: chronic discoid lupus erythematosus.
(05 Mar 2000)
disseminated lupus erythematosus <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma.
Immune complex deposition in the glomerular capillaries is a particular problem.
Acronym: SLE
(19 Jan 1998)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
lupus A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis.
(27 Sep 1997)
lupus anticoagulant An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus.
(27 Sep 1997)
lupus anticoagulants Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT).
Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area.
See also cardiolipin antibodies and phospholipid antibodies.
(05 Mar 2000)
lupus band test A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell <pathology> Phagocyte that has ingested nuclear material of another cell: characteristic of systemic lupus erythematosus.
(18 Nov 1997)
lupus erythematosus cell test <investigation> A test for lupus that measures the presence of autoantibodies against nuclear proteins in the blood. Performed on a normal venipuncture specimen, this test is positive in 70 to 80% of patients with lupus. Some patients with rheumatoid arthritis, scleroderma and drug-induced lupus may also have a positive test result.
(27 Sep 1997)
lupus erythematosus, cutaneous A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= lupus erythematosus, systemic with skin lesions), subacute, and chronic (= lupus erythematosus, discoid).
(12 Dec 1998)
lupus erythematosus, discoid A chronic form of cutaneous lupus erythematosus (lupus erythematosus, cutaneous) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterised by the presence of discoid skin plaques showing varying degrees of oedema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
(12 Dec 1998)
lupus erythematosus profundus A subcutaneous panniculitis with marked lymphocyte infiltration of fat lobules giving rise to deep-seated, firm, rubbery nodules that sometimes become ulcerated, usually of the face; may occur in systemic and localised lupus erythematosus.
Synonym: lupus profundus.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Montessori method(system)
    (ÀÌÅ»¸®¾ÆÀÇ ¿©¼º ±³À°°¡ À̸§¿¡¼­) ¸óÅ×¼Ò¸®½Ä ±³À°¹ý(¾Æµ¿ÀÇ ÀÚÁÖ¼ºÀÇ ½ÅÀåÀ» Áß½ÃÇÑ ±³À°¹ý) m`
  • PA system
    =PUBLICADDRESS SYSTEM
  • Ptolemaic system
    õµ¿¼³
  • ascent propulsion system
    ¿ìÁÖ Á¤°ÅÀå ±Íȯ¿ë ·ÎÄÏ ¿£Áø
  • barter system
    ¹ÙÅÍÁ¦
  • call connect system
    ÀüÈ­ Á¢¼Ó±â(¿Ü¼±.³»¼± ÀüÈ­¿ÍÀÇ)
  • case system
    ÆÇ·Ê Áß½ÉÀÇ ±³À°¹ý 1
  • centerofmass system
    Á߽ɰè(°èÀÇ Áß½ÉÀÇ ¿îµ¿·®ÀÌ ¿µÀÌ µÇµµ·Ï ÃëÇÑ ÁÂÇ¥°è)
  • chit system
    ÀüÇ¥ ÁöºÒÁ¦
  • circulatory system
    ¼øÈ¯°è(Ç÷¾×À̳ª ¸²ÇÁ¾×ÀÌ È帣°Ô ÇÏ´Â)
  • closed ecological system
    »ýÅÂÇÐÀû Æó¼â°è
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • container system
    ÄÁÅ×ÀÌ³Ê ¼ö¼Û¹æ½Ä
  • convict system
    ¡¿ª(À¯Çü)Á¦µµ
  • coupon system
    °æÇ°ºÎ ÆÇ¸Å¹ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á